Oncothyreon Expands Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Prostate Cancer

SEATTLE, Sept. 5, 2012 /PRNewswire/ – Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer …

Posted in Uncategorized